Cimetidine

"目录号: HY-14289

GPCR/G ProteinImmunology/Inflammation|

Cimetidine是H2受体拮抗剂。

Histamine Receptor

相关产品

Pitolisant hydrochloride|Perphenazine|Osthole|Clemastine fumarate|Clemizole hydrochloride|Promethazine hydrochloride|Azelastine hydrochloride|Bepotastine Beslilate|Diphenylpyraline hydrochloride|Famotidine|Histamine|Alcaftadine|Bilastine|Cetirizine dihydrochloride|Desloratadine|

生物活性

Description

Cimetidine is a histamine-2 (H2) receptor antagonist.IC50 Value: Target: Histamine-2 Receptorin vitro: Cimetidine, a partial agonist for H2R, has a pharmacological profile different from ranitidine and famotidine, possibly contributing to its antitumor activity on gastrointestinal cancers [1]. Cimetidine had no effect on the uptake and cytotoxicity of cisplatin in ovarian cancer cells with high OCT2 mRNA levels (IGROV-1 cells) [2]. Cimetidine showed no effect on proliferation, survival, migration and invasion of 3LL cells. Cimetidine reversed MDSC-mediated T-cell suppression, and improved IFN-γ production. [3]. Cimetidine-mediated down-regulation of NCAM involved suppression of the nuclear translocation of NF-kappaB, a transcriptional activator of NCAM gene expression [4].in vivo: the antitumor efficacy of cisplatin in mice bearing luciferase-tagged IGROV-1 xenografts was unaffected by cimetidine (P = 0.39). Data obtained in 18 patients receiving cisplatin (100 mg/m(2)) in a randomized crossover fashion with or without cimetidine (800 mg × 2) revealed that cimetidine did not alter exposure to unbound cisplatin [2]. cimetidine reduced CD11b(+)Gr-1(+) myeloid derived-suppressive cell (MDSC) accumulation in spleen, blood and tumor tissue of tumor-bearing mice [3]. Cimetidine exerts a beneficial effect on periodontal disease in rats, decreasing the RANKL/OPG ratio in gingival connective tissue and reducing alveolar bone resorption [5].

Clinical Trial

NCT00475059

Centre Hospitalier Universitaire de Saint Etienne

Kidney Transplantation

March 2007

NCT01536249

Knopp Biosciences

Amyotrophic Lateral Sclerosis

March 2012

Phase 1

NCT01256879

University of Maryland|Food and Drug Administration (FDA)

Healthy

March 2011

Phase 1

NCT02287272

Chiesi Farmaceutici S.p.A.

COPD

May 2014

Phase 1

NCT00800280

Pfizer

Generalized Anxiety Disorder

January 2009

Phase 1

NCT00002092

Community Research Initiative of New England|NIH AIDS Clinical Trials Information Service

HIV Infections

NCT02157376

AstraZeneca

Stress Ulcer Prophylaxis

July 2014

Phase 3

NCT02172417

Boehringer Ingelheim

Healthy

July 2000

Phase 1

NCT01010698

University of Maryland|Food and Drug Administration (FDA)

Healthy

June 2009

Phase 1

NCT00045799

Valeant Pharmaceuticals International, Inc.

Upper Gastrointestinal Bleeding

May 2002

Phase 3

NCT01757275

AstraZeneca

Bleeding Peptic Ulcer

February 2013

Phase 3

NCT02202512

Boehringer Ingelheim

Healthy

September 2014

Phase 1

NCT02555852

Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)

Gastroesophageal Reflux Disease (GERD)|Community-acquired Pneumonia

September 2011

NCT00002733

Hoag Memorial Hospital Presbyterian

Kidney Cancer|Melanoma (Skin)|Unspecified Adult Solid Tumor, Protocol Specific

January 1996

Phase 2

NCT00515073

M.D. Anderson Cancer Center

Endometrial Cancer

April 2001

Phase 2

NCT00475059

Centre Hospitalier Universitaire de Saint Etienne

Kidney Transplantation

March 2007

NCT01536249

Knopp Biosciences

Amyotrophic Lateral Sclerosis

March 2012

Phase 1

NCT01256879

University of Maryland|Food and Drug Administration (FDA)

Healthy

March 2011

Phase 1

NCT02287272

Chiesi Farmaceutici S.p.A.

COPD

May 2014

Phase 1

NCT00800280

Pfizer

Generalized Anxiety Disorder

January 2009

Phase 1

NCT00002092

Community Research Initiative of New England|NIH AIDS Clinical Trials Information Service

HIV Infections

NCT02157376

AstraZeneca

Stress Ulcer Prophylaxis

July 2014

Phase 3

NCT02172417

Boehringer Ingelheim

Healthy

July 2000

Phase 1

NCT01010698

University of Maryland|Food and Drug Administration (FDA)

Healthy

June 2009

Phase 1

NCT00045799

Valeant Pharmaceuticals International, Inc.

Upper Gastrointestinal Bleeding

May 2002

Phase 3

NCT01757275

AstraZeneca

Bleeding Peptic Ulcer

February 2013

Phase 3

NCT02202512

Boehringer Ingelheim

Healthy

September 2014

Phase 1

NCT02555852

Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)

Gastroesophageal Reflux Disease (GERD)|Community-acquired Pneumonia

September 2011

NCT00002733

Hoag Memorial Hospital Presbyterian

Kidney Cancer|Melanoma (Skin)|Unspecified Adult Solid Tumor, Protocol Specific

January 1996

Phase 2

NCT00515073

M.D. Anderson Cancer Center

Endometrial Cancer

April 2001

Phase 2

View MoreCollapse

References

[1].Takahashi, H.K., et al., Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol, 2006. 70(2): p. 450-3.

[2].Sprowl, J.A., et al., Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther, 2013. 94(5): p. 585-92.

[3].Zheng, Y., et al., Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol, 2013. 54(1): p. 74-83.

[4].Fukuda, M., K. Kusama, and H. Sakashita, Cimetidine inhibits salivary gland tumor cell adhesion to neural cells and induces apoptosis by blocking NCAM expression. BMC Cancer, 2008. 8: p. 376.

[5].Longhini, R., et al., Cimetidine Reduces the Alveolar Bone Loss in Induced Periodontitis in Rat Molars. J Periodontol, 2013.

最后编辑于
©著作权归作者所有,转载或内容合作请联系作者
【社区内容提示】社区部分内容疑似由AI辅助生成,浏览时请结合常识与多方信息审慎甄别。
平台声明:文章内容(如有图片或视频亦包括在内)由作者上传并发布,文章内容仅代表作者本人观点,简书系信息发布平台,仅提供信息存储服务。

相关阅读更多精彩内容

友情链接更多精彩内容